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the Netherlands Reference Laboratory for Bacterial Men-
ingitis. Standard methods for cost-effectiveness analysis
were used. Analysis was done from a societal perspective,
including direct and indirect costs of productivity loss
(friction-costs method; price levels in 1998 €; discount
rate of 4%). Cost-effectiveness ratios were expressed in
net costs per quality adjusted life year (QALY) gained.
Sensitivity analysis was performed on several key param-
eters of the model. RESULTS: In the base-case, through
vaccination 480 QALYs are gained, while total net costs
of the program are €5,546,923. The cost-effectiveness ra-
tio is €11,600 per QALY gained. Sensitivity analysis indi-
cates a cost-effectiveness range of €5,841 to 30,543 per
QALY gained. CONCLUSIONS: Vaccination of all new-
borns with meningococcal OMV vaccine has an accept-
able cost-effectiveness ratio compared to other interven-
tions in the Netherlands.
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OBJECTIVE:
 
 To provide a preliminary assessment of the
economic value of vaccinating 1-year old children against
varicella in Germany. METHODS: We developed a deci-
sion-analytic model to compare the clinical and economic
outcomes of a universal varicella vaccination program
versus no vaccination in infants. The model predicts the
clinical effects, direct and indirect costs, and the cost-effec-
tiveness of mass vaccination. Model input data were
mainly derived from a large survey conducted across Ger-
many and were complemented by literature data and ex-
pert estimates. In the survey, pediatricians, GP’s and
internists provided information extracted from 1334 ran-
domly selected varicella patient records. Epidemiological
data but also medical resource utilization such as physi-
cian consultations, medication, and hospitalization due
to disease complications was captured. Additionally,
work loss of caregivers and infected employed individu-
als was retrieved from the records. Since the survey was
completed only very recently, the analysis of the model
input data is preliminary. Valuation of the resources used
was done by applying unit costs obtained from official
medical tariff lists, drug compendiums, and other statis-
tics. Vaccine efficacy was assumed to be between 90%
and 97%, and vaccination coverage between 50% and
80%. Future costs were discounted at 5%. The perspec-
tive taken is that of the society. RESULTS: The prelimi-
nary findings presented here apply to a timeframe of 30
years. Over that period, the model predicts that universal
children vaccination could prevent between 7.4 and 11.2
million varicella infections, and between 53,000 and
88,000 major complications depending on the assump-
tions taken. Universal vaccination also appears to be eco-
nomically worthwhile with a benefit-cost ratio of be-
tween 2.1 and 1.9. CONCLUSIONS: These preliminary
results suggests that universal varicella vaccination pro-
vide significant clinical and economic benefits to the Ger-
man society. A final analysis is in process, which will be
an important information source for healthcare decision-
makers.
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OBJECTIVE
 
: To assess avoidable hospitalization as an
outcome indicator of access to and quality of primary
care by examining trends and gender and ethnic varia-
tions. METHOD: Aggregated nationwide data on annual
hospital discharges in Singapore from 1991 to 1998 were
collected from the Central Claims Processing System
(CCPS) database. They included total hospitalizations
(excluding maternity and psychiatric disorders) and hos-
pitalizations for chronic diseases, which are avoidable by
timely, appropriate and effective primary care (ambula-
tory care sensitive (ACS) conditions): asthma, congestive
heart failure, chronic obstructive pulmonary disease, dia-
betes mellitus and hypertension. Directly age-standard-
ized rates were adjusted for gender and ethnic differences
in total hospitalizations. RESULTS: From 1991 to 1998,
(total of 1,479,494 hospitalizations), 6.7% were for ACS
conditions. Overall, the annual rate of avoidable hospi-
talization was 29.4 per 10,000 population. Women had
lower rates of avoidable hospitalizations than males
(22.4 versus 29.5 per 10,000), as well as for total hospi-
talizations (496.2 versus 515.5 per 10,000). Adjusted for
total hospitalization, males were 1.3 times more likely
than females to be hospitalized for ACS conditions.
Compared to Chinese, Indian and Malays had higher
rates of avoidable hospitalizations (21.7, 65.5 and 56.1 per
10,000 respectively). Adjusting for their higher rates of
total hospitalization, they were 1.7 and 1.8 times respec-
tively more likely than Chinese to be admitted for ACS
conditions. Avoidable hospitalization decline (adjusted
for total hospitalization) was 9.1% overall; greater in
males (11.8%) than in females (5.3%); greater for
Chinese (15.8%), than Malays (1.1%) and Indians
(increase of 4.3%). Among Malays and Indians,
women showed marked increases of avoidable hospital-
izations, 10.8% and 8.1% respectively. CONCLU-
